PF-Atlas › Drugs › Ruxolitinib

Ruxolitinib

Idiopathic Pulmonary Fibrosis · Blocks SASP cytokine signaling (IL-6, IL-8) without killing senescent cells

Mechanism
Blocks SASP cytokine signaling (IL-6, IL-8) without killing senescent cells
Development stage
Phase I/II
Evidence level
Level 2 (Repositioning)
Developer
Incyte / Multiple

Overview

FDA-approved for GVHD. Blocks JAK1/2 downstream of SASP. Seno-morphic approach. Generic available.

Explore related

Treatment profileBlocks SASP cytokine signaling (IL-6, IL-8) without killing senescent cellsAll trialsResearch
Medical disclaimer. This page summarizes research about Ruxolitinib for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.